
How clinicians assess low testosterone alongside symptoms, health conditions and medicines, with repeat testing and context for free testosterone and SHBG.

Low testosterone, also called testosterone deficiency, is a condition assessed through consistently low testosterone levels together with compatible signs and symptoms. The European Association of Urology (EAU) uses both the clinical picture and blood measurements when evaluating adult men.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret individual results and make testing or treatment decisions. Do not stop prescribed medicines or begin testosterone on the basis of educational content.
The reference-range question to bring to a clinician is: “How does my result compare with the range for the reported test, and what does that mean in my case?” That discussion should cover what was measured as well as the symptoms that led to testing.
Biologically, the assessment considers whether testosterone production or action is impaired. The EAU requires compatible signs and symptoms alongside consistently low testosterone. A result marked low on a laboratory report is therefore not the full diagnosis or an automatic reason to start treatment.
The EAU recommends measuring testosterone in the morning while fasting, using a reliable assay. It also recommends repeating the measurement when a result is low. These conditions belong in the interpretation of the result rather than being treated as administrative details.
For someone reviewing an initial result, useful questions include whether the sample met those conditions and whether confirmation is needed. Understanding the circumstances around a first testosterone test helps frame that conversation without assigning a diagnosis to the number.
A 2026 review in Nature Reviews Urology notes that free testosterone and sex hormone-binding globulin (SHBG) measurements may help clarify borderline results. They may also help when symptoms and total testosterone do not align.
The practical question is what uncertainty an additional measurement would address. A discussion about total testosterone and its related binding protein should connect the measurements to the clinical question, rather than assume that every man needs every available test.
A clinical review of testosterone deficiency identifies several common complaints that can arise during an assessment:
The review describes these as less specific than sexual and reproductive manifestations because they have alternative explanations. They deserve attention, but they do not establish that testosterone is the reason a man feels unwell.
This distinction matters when symptoms are the main reason for seeking a test. A useful medical discussion keeps the symptom history alongside the laboratory findings. It does not force all complaints into a hormone explanation before other possibilities have been considered.
For the consultation, describe the changes that prompted concern and mention any sexual or reproductive concerns as well. The aim is to give the clinician a clear account of the problem being assessed. The EAU's framework brings that account together with the blood measurements rather than treating either as a substitute for the other.
The EAU describes functional hypogonadism as impaired testosterone production associated with other health conditions or medicines in adulthood. It is a diagnosis of exclusion, meaning organic causes must be ruled out before that label is used. The Nature Reviews Urology review also distinguishes primary, secondary and functional hypogonadism as different categories.
An association does not prove what caused an individual man's result. Obesity or another health condition is a reason to investigate the wider picture, not a complete explanation by itself. This is why distinguishing potentially reversible suppression from hormone-gland disorders belongs in a clinical evaluation.
The clinical review lists obesity among possible contributors to functional secondary hypogonadism. The Nature Reviews Urology review also describes obesity as commonly associated with functional hypogonadism. The EAU recommends addressing excess weight and relevant lifestyle factors before testosterone therapy where appropriate.
The clinical question is how weight fits with the rest of the assessment. A discussion should still include symptoms and confirmed measurements, along with other health conditions and medicines. Weight deserves consideration without becoming a shortcut that replaces the broader evaluation.
The clinical review includes sleep disorders among possible contributors to functional secondary hypogonadism. It also identifies improved sleep as part of first-line management in functional hypogonadism.
A known sleep disorder is therefore relevant information for the clinician reviewing testosterone. It belongs in the same conversation as the symptoms that prompted testing and the other conditions already being treated. The useful question is how sleep-related care fits into the overall assessment, rather than whether a hormone result should be considered in isolation.
The clinical review lists acute or chronic systemic illness among possible contributors. The EAU specifically advises against measuring testosterone during acute illness because acute disease can be associated with functional hypogonadism.
If a sample was taken during an acute illness, bring that timing to the clinician's attention and ask how it affects interpretation. This gives the clinician important context before conclusions are drawn from the measurement.
Chronic illness also belongs in the review. The EAU recommends checking coexisting diseases that could interfere with testosterone production or action. A consultation can therefore address the underlying condition and the hormone question together, rather than treating them as unrelated problems.
The clinical review identifies these medicine groups as possible reversible contributors:
The EAU's recommendation is broader than those examples. It calls for checking diseases and medicines, as well as substances that may interfere with testosterone production or action. Bring the relevant medication and substance history into the discussion rather than deciding independently which items matter.
The EAU recommends considering withdrawal of medicines that impair testosterone production where possible before starting testosterone therapy. That is a decision for the prescribing clinician. A suspected medication contribution is a reason for medical review, not a reason to stop a prescribed treatment independently.
The clinical review describes the following as first-line measures in functional hypogonadism:
The EAU similarly recommends addressing relevant lifestyle factors and excess weight before testosterone therapy where appropriate. Its guidance also includes reviewing medicines and managing coexisting disease.
“Potentially reversible” describes a possibility rather than an individual outcome. The review's summary does not establish that these measures will restore testosterone or resolve symptoms for every man.
For a clinical conversation, the next question is which identified contributors deserve attention and how the clinician will assess their relevance. That keeps the discussion tied to actual findings. It also separates care for an underlying health problem from a promise about what the next testosterone result will show.
Ask your physician: “Do my symptoms and repeat morning results support testosterone deficiency?” “Could my conditions or medicines contribute?” “Would free testosterone or SHBG clarify the result?” “What underlying issues should be evaluated before treatment is considered?”
Reviewing medicines alongside a low testosterone result is the prescribing clinician's responsibility; Testostra adds clear educational context about the biomarkers involved. For men comparing total testosterone with free testosterone and SHBG, its evidence-led reporting helps explain the distinctions without supplying a diagnosis or directing changes to prescribed treatment.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra